Dr. Mustafa Madbouli, Prime Minister of the Cabinet, met with Dr. Ali Al-Ghamrawy, President of the Egyptian Pharmaceutical Authority, at the government headquarters in the new city of Al-Amein yesterday evening, to review a report on the availability of medicines in the Egyptian market.
At the end of the meeting, the Prime Minister pointed out that his meeting today with the head of the Pharmaceutical Board comes in the framework of the periodic follow-up of the developments of the drug supply profile in the Egyptian market, it is clear that the government has made a lot of efforts in the past months to make the medicines available through the facilitation of customs clearance of these medicines and the release of substances The raw materials required for the manufacturing process, which contribute to the market needs of medicines.
Dr. Mustafa Madbouli asserted that the pharmaceutical industry is one of the priority industries for the government, as part of efforts to support the pharmaceuticals industry in particular and to support the industry sector in general during the current phase.
In his turn, Dr. Ali Al-Ghamrawy confirmed that the body is doing its best to make the medicine available in the Egyptian market, indicating that the body has already succeeded in increasing the supply of the medicine, and that the supply of some remaining varieties of the medicines is being completed within the next few weeks.
During the meeting, the President of the Egyptian Pharmaceutical Authority reviewed the cooperation efforts between the body and the World Health Organization, as well as its efforts to support the pharmaceutical industry in accordance with global standards.
As the “extraordinary” has considered the body’s efforts in the field of machinery and digital transformation, it is clear that these efforts come in the framework of the keenness to keep up with the latest technological developments globally.
He also noted the efforts of the Pharmaceutical Authority in collaboration with the Unified Procurement Authority to work on domesticating modern technology in the field of pharmaceutical manufacturing.
